<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Clinical studies that reported anti-viral therapy in management of COVID-19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">First author; Year; Country</th>
    <th align="left" rowspan="1" colspan="1">Sample size</th>
    <th align="left" rowspan="1" colspan="1">Age (year)*</th>
    <th align="left" rowspan="1" colspan="1">Male</th>
    <th align="left" rowspan="1" colspan="1">Status of patients</th>
    <th align="left" rowspan="1" colspan="1">Antiviral agent</th>
    <th align="left" rowspan="1" colspan="1">Antiviral treated patients (n)</th>
    <th align="left" rowspan="1" colspan="1">Dosage</th>
    <th align="left" rowspan="1" colspan="1">Route of administration</th>
    <th align="left" rowspan="1" colspan="1">Duration of treatment</th>
    <th align="left" rowspan="1" colspan="1">Combination</th>
    <th align="left" rowspan="1" colspan="1">Main findings</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" colspan="12" rowspan="1">
     <bold>Randomized clinical trial</bold>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Cao et al; 2020; China (10)</td>
    <td align="left" rowspan="1" colspan="1">199</td>
    <td align="left" rowspan="1" colspan="1">58 (50 to 68)</td>
    <td align="left" rowspan="1" colspan="1">120</td>
    <td align="left" rowspan="1" colspan="1">Severe COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/Ritonavir</td>
    <td align="left" rowspan="1" colspan="1">99</td>
    <td align="left" rowspan="1" colspan="1">400 mg/100 mg twice daily </td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">14</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir–ritonavir administration is not superior to standard care in management of adult patients with severe COVID-19. Clinical improvement and mortality rate are similar in lopinavir–ritonavir treated and standard care groups.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Case-series</td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Chen N; 2020; China (11)</td>
    <td align="left" rowspan="1" colspan="1">99</td>
    <td align="left" rowspan="1" colspan="1">21 to 82</td>
    <td align="left" rowspan="1" colspan="1">67</td>
    <td align="left" rowspan="1" colspan="1">COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="left" rowspan="1" colspan="1">75</td>
    <td align="left" rowspan="1" colspan="1">75 mg twice a day</td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">3 to 14 </td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Recovery rate: 31%; Mortality rate: 11%</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Chen Q; 2020; China (12)</td>
    <td align="left" rowspan="1" colspan="1">9</td>
    <td align="left" rowspan="1" colspan="1">14 to 56</td>
    <td align="left" rowspan="1" colspan="1">5</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ Ritonavir</td>
    <td align="left" rowspan="1" colspan="1">9</td>
    <td align="left" rowspan="1" colspan="1">800 mg/200 mg daily</td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">4 to 11</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">No mortality. Time from onset of treatment to negative result of Cov-test was 4-11 days. Length of hospital stay was 9 to 20 days.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Guan W; 2020; China (13)</td>
    <td align="left" rowspan="1" colspan="1">1099</td>
    <td align="left" rowspan="1" colspan="1">47.0 (IQR: 35.0–58.0)</td>
    <td align="left" rowspan="1" colspan="1">637</td>
    <td align="left" rowspan="1" colspan="1">Non-severe and severe COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="left" rowspan="1" colspan="1">393</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Administration of oseltamivir did not decrease ICU admission and need for ventilator or death</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Hu Z; 2020; China (15) </td>
    <td align="left" rowspan="1" colspan="1">24</td>
    <td align="left" rowspan="1" colspan="1">5 to 95 </td>
    <td align="left" rowspan="1" colspan="1">8</td>
    <td align="left" rowspan="1" colspan="1">Asymptomatic COVID-19 infection</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">21</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">No mortality, no ICU admission, no severe complication</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Huang C; 2020; China (16)</td>
    <td align="left" rowspan="1" colspan="1">41</td>
    <td align="left" rowspan="1" colspan="1">49 (IQR 41·0–58·0)</td>
    <td align="left" rowspan="1" colspan="1">30</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="left" rowspan="1" colspan="1">38</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">6 patients died 28 patients were discharged</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Liu K; 2020; China (19)</td>
    <td align="left" rowspan="1" colspan="1">137</td>
    <td align="left" rowspan="1" colspan="1">20 to 83</td>
    <td align="left" rowspan="1" colspan="1">61</td>
    <td align="left" rowspan="1" colspan="1">Severe COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">105</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">16 patients died during the study.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Liu L; 2020; China (20)</td>
    <td align="left" rowspan="1" colspan="1">51</td>
    <td align="left" rowspan="1" colspan="1">16 to 68</td>
    <td align="left" rowspan="1" colspan="1">32</td>
    <td align="left" rowspan="1" colspan="1">Discharged COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ Ritonavir
     <break/>Oseltamivir
     <break/>Arbidol
    </td>
    <td align="left" rowspan="1" colspan="1">51
     <break/>7
     <break/>2
    </td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Duration of hospital stay was 9-13 days. 1 patient died.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Qin X; 2020; China (21)</td>
    <td align="left" rowspan="1" colspan="1">89</td>
    <td align="left" rowspan="1" colspan="1">23 to 86</td>
    <td align="left" rowspan="1" colspan="1">45</td>
    <td align="left" rowspan="1" colspan="1">All COVID-19 patients admitted to a center</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/Ritonavir
     <break/>Other anti-viral
    </td>
    <td align="left" rowspan="1" colspan="1">84
     <break/>5
    </td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">16 patients were discharged and 1 patient died.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Shang J; 2020; China (22)</td>
    <td align="left" rowspan="1" colspan="1">416</td>
    <td align="left" rowspan="1" colspan="1">49 (IQR: 36-61)</td>
    <td align="left" rowspan="1" colspan="1">194</td>
    <td align="left" rowspan="1" colspan="1">Survived and dead COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">380</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Anti-viral administration did not affect mortality rate (5.6% in non-treated vs. 12.9 treated; p=0.288)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Wang D; 2020; China (23)</td>
    <td align="left" rowspan="1" colspan="1">138</td>
    <td align="left" rowspan="1" colspan="1">22 to 92</td>
    <td align="left" rowspan="1" colspan="1">75</td>
    <td align="left" rowspan="1" colspan="1">ICU and Non-ICU admitted COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="left" rowspan="1" colspan="1">124</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">6 patients died and 36 patients were admitted to ICU.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Wu J; 2020; China (25)</td>
    <td align="left" rowspan="1" colspan="1">80</td>
    <td align="left" rowspan="1" colspan="1">46.10 ± 15.42</td>
    <td align="left" rowspan="1" colspan="1">39</td>
    <td align="left" rowspan="1" colspan="1">All severity ranges of COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Ribavirin</td>
    <td align="left" rowspan="1" colspan="1">80</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">2-12 days</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">21 patients were discharged and 59 patients remained in hospital.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Xu X; 2020; China (26)</td>
    <td align="left" rowspan="1" colspan="1">62</td>
    <td align="left" rowspan="1" colspan="1">41 (IQR: 32-52)</td>
    <td align="left" rowspan="1" colspan="1">35</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir
     <break/>Arbidol
     <break/>Lopinavir/ritonavir + Arbidol
    </td>
    <td align="left" rowspan="1" colspan="1">25
     <break/>1
     <break/>21
    </td>
    <td align="left" rowspan="1" colspan="1">Lopinavir 400 mg twice daily ritonavir 100 mg twice daily
     <break/>Arbidol 200 mg three time daily
    </td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">One patient was discharged. Other patients remained in hospital</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Yang W; 2020; China (27)</td>
    <td align="left" rowspan="1" colspan="1">149</td>
    <td align="left" rowspan="1" colspan="1">45.11 ± 13.35</td>
    <td align="left" rowspan="1" colspan="1">81</td>
    <td align="left" rowspan="1" colspan="1">All COVID-19 patients admitted to a center</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">140</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">No mortality. 73 patients were discharged and 76 remained in hospital.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Young BE; 2020; Singapore (28)</td>
    <td align="left" rowspan="1" colspan="1">18</td>
    <td align="left" rowspan="1" colspan="1">31 to 73</td>
    <td align="left" rowspan="1" colspan="1">9</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir</td>
    <td align="left" rowspan="1" colspan="1">5</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Two patients recovered and the condition of 2 other patients deteriorated. Only one patient completed the 12-day planned protocol. Four patients experienced side effects of antiviral therapy</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zhang G; 2020; China (29)</td>
    <td align="left" rowspan="1" colspan="1">221</td>
    <td align="left" rowspan="1" colspan="1">20 to 96</td>
    <td align="left" rowspan="1" colspan="1">108</td>
    <td align="left" rowspan="1" colspan="1">Non-severe and severe confirmed COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">196</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">12 patients died. Chest CT improved after administration of ECMO and IMV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zhou Z; 2020; China (31)</td>
    <td align="left" rowspan="1" colspan="1">10</td>
    <td align="left" rowspan="1" colspan="1">29 to 68</td>
    <td align="left" rowspan="1" colspan="1">8</td>
    <td align="left" rowspan="1" colspan="1">Confirmed COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir
     <break/>Arbidol
    </td>
    <td align="left" rowspan="1" colspan="1">8
     <break/>3
    </td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">1 patient died, 5 patients remained hospitalized and 4 patients were discharged</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Case reports</td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Han X; 2020; China (14)</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">23</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">Diabetic patient with COVID-19 </td>
    <td align="left" rowspan="1" colspan="1">Oseltamivir/ Gancivlovire</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">15</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Patient was discharged from hospital after 15 days</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Li W; 2020; China (17) </td>
    <td align="left" rowspan="1" colspan="1">5</td>
    <td align="left" rowspan="1" colspan="1">10 months to 6 years</td>
    <td align="left" rowspan="1" colspan="1">4</td>
    <td align="left" rowspan="1" colspan="1">Children with COVID-19</td>
    <td align="left" rowspan="1" colspan="1">Not specified</td>
    <td align="left" rowspan="1" colspan="1">2</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">The antiviral therapy did not change the outcome or length of stay</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Lim J; 2020; South Korea (18)</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">54</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19 patient</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">75 mg twice a day/50 mg twice daily</td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">9</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Good recovery. It is not clear that the decreased load of virus is due to the nature of healing process or a result of anti-viral therapy</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Wang Z; 2020; China (24)</td>
    <td align="left" rowspan="1" colspan="1">4</td>
    <td align="left" rowspan="1" colspan="1">19 to 63</td>
    <td align="left" rowspan="1" colspan="1">3</td>
    <td align="left" rowspan="1" colspan="1">COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir 
     <break/>Arbidol
     <break/>SFJDC
    </td>
    <td align="left" rowspan="1" colspan="1">4</td>
    <td align="left" rowspan="1" colspan="1">400 mg/100 mg twice daily
     <break/>0.2 g, three time daily
     <break/>2.08 g, three time daily
    </td>
    <td align="left" rowspan="1" colspan="1">Oral</td>
    <td align="left" rowspan="1" colspan="1">6-16 days</td>
    <td align="left" rowspan="1" colspan="1">Antibiotic</td>
    <td align="left" rowspan="1" colspan="1">2 patients recovered and 2 patients remained in hospital</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Zhang Z; 2020; China (30)</td>
    <td align="left" rowspan="1" colspan="1">2</td>
    <td align="left" rowspan="1" colspan="1">38</td>
    <td align="left" rowspan="1" colspan="1">1</td>
    <td align="left" rowspan="1" colspan="1">Symptomatic COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">oseltamivir and Arbidol</td>
    <td align="left" rowspan="1" colspan="1">2</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">NR</td>
    <td align="left" rowspan="1" colspan="1">Yes</td>
    <td align="left" rowspan="1" colspan="1">Both patients recovered and were discharged</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>*,Age was reported as range, mean±SD or median (interquartile rang [IQR]). ECMO: extracorporeal membrane oxygenation; IMV: invasive mechanical ventilation; NR: Not reported; ICU: intensive care unit; CT: computed tomography</p>
 </table-wrap-foot>
</table-wrap>
